Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ceralasertib (AZD6738)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AstraZeneca

Drug class:

ATR inhibitor

Related drugs:

BRCA1 mutation	HER2 Negative Breast Cancer	BRCA1 mutation	HER2 Negative Breast Cancer	olaparib + AZD6738 Sensitive: C3 – Early Trials olaparib + AZD6738 Sensitive : C3	olaparib + AZD6738 Sensitive: C3 – Early Trials olaparib + AZD6738 Sensitive : C3
BRCA2 mutation	HER2 Negative Breast Cancer	BRCA2 mutation	HER2 Negative Breast Cancer	olaparib + AZD6738 Sensitive: C3 – Early Trials olaparib + AZD6738 Sensitive : C3	olaparib + AZD6738 Sensitive: C3 – Early Trials olaparib + AZD6738 Sensitive : C3
NRAS mutation	Melanoma	NRAS mutation	Melanoma	AZD6738 Sensitive: C3 – Early Trials AZD6738 Sensitive : C3	AZD6738 Sensitive: C3 – Early Trials AZD6738 Sensitive : C3
NF1 mutation	Colorectal Cancer	NF1 mutation	Colorectal Cancer	AZD6738 Sensitive: C3 – Early Trials AZD6738 Sensitive : C3	AZD6738 Sensitive: C3 – Early Trials AZD6738 Sensitive : C3
ARID1A mutation	Solid Tumor	ARID1A mutation	Solid Tumor	AZD6738 Sensitive: C3 – Early Trials AZD6738 Sensitive : C3	AZD6738 Sensitive: C3 – Early Trials AZD6738 Sensitive : C3
ATM mutation	Ovarian Cancer	ATM mutation	Ovarian Cancer	olaparib + AZD6738 Sensitive: C3 – Early Trials olaparib + AZD6738 Sensitive : C3	olaparib + AZD6738 Sensitive: C3 – Early Trials olaparib + AZD6738 Sensitive : C3
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	olaparib + AZD6738 Sensitive: C3 – Early Trials olaparib + AZD6738 Sensitive : C3	olaparib + AZD6738 Sensitive: C3 – Early Trials olaparib + AZD6738 Sensitive : C3
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	olaparib + AZD6738 Sensitive: C3 – Early Trials olaparib + AZD6738 Sensitive : C3	olaparib + AZD6738 Sensitive: C3 – Early Trials olaparib + AZD6738 Sensitive : C3
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	durvalumab + AZD6738 Sensitive: C3 – Early Trials durvalumab + AZD6738 Sensitive : C3	durvalumab + AZD6738 Sensitive: C3 – Early Trials durvalumab + AZD6738 Sensitive : C3
PGBD5 overexpression	Neuroblastoma	PGBD5 overexpression	Neuroblastoma	AZD6738 Sensitive: D – Preclinical AZD6738 Sensitive : D	AZD6738 Sensitive: D – Preclinical AZD6738 Sensitive : D
PGBD5 underexpression	Neuroblastoma	PGBD5 underexpression	Neuroblastoma	AZD6738 Sensitive: D – Preclinical AZD6738 Sensitive : D	AZD6738 Sensitive: D – Preclinical AZD6738 Sensitive : D
IDH1 R132H	Glioma	IDH1 R132H	Glioma	olaparib + AZD6738 Sensitive: D – Preclinical olaparib + AZD6738 Sensitive : D	olaparib + AZD6738 Sensitive: D – Preclinical olaparib + AZD6738 Sensitive : D
BRAF V600	Melanoma	BRAF V600	Melanoma	olaparib + AZD6738 Sensitive: D – Preclinical olaparib + AZD6738 Sensitive : D	olaparib + AZD6738 Sensitive: D – Preclinical olaparib + AZD6738 Sensitive : D
BRAF V600	Melanoma	BRAF V600	Melanoma	AZD6738 Sensitive: D – Preclinical AZD6738 Sensitive : D	AZD6738 Sensitive: D – Preclinical AZD6738 Sensitive : D
SLFN11 underexpression	Small Cell Lung Cancer	SLFN11 underexpression	Small Cell Lung Cancer	AZD6738 + lurbinectedin Sensitive: D – Preclinical AZD6738 + lurbinectedin Sensitive : D	AZD6738 + lurbinectedin Sensitive: D – Preclinical AZD6738 + lurbinectedin Sensitive : D
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	olaparib + AZD6738 Sensitive: D – Preclinical olaparib + AZD6738 Sensitive : D	olaparib + AZD6738 Sensitive: D – Preclinical olaparib + AZD6738 Sensitive : D